

FORM NRC-313M (B-78) 10 CFR 35	U.S. NUCLEAR REGULATORY COMMISSION APPLICATION FOR MATERIALS LICENSE – MEDICAL	Approved GAO R0557			
INSTRUCTIONS – Complete Items 1 through 26 if this is an initial application or an application for renewal of a license. Use supplemental sheets where necessary. Item 26 must be completed on all applications and signed. Retain one copy. Submit original and one copy of entire application to: Director, Office of Nuclear Materials Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, D.C. 20545. Upon approval of this application, the applicant will receive a Materials License. An NRC Materials License is issued in accordance with the general requirements contained in Title 10, Code of Federal Regulations, Part 30, and the Licensee is subject to Title 10, Code of Federal Regulations, Parts 19, 20 and 35 and the license fee provision of Title 10, Code of Federal Regulations, Part 170. The license fee category should be stated in Item 26 and the appropriate fee enclosed.					
1.a. NAME AND MAILING ADDRESS OF APPLICANT (institution, firm, clinic, physician, etc.) INCLUDE ZIP CODE <div style="text-align: center;"> Glenwood Medical Group 2000 Glenwood Avenue Jolie, Illinois 60435 </div> TELEPHONE NO.: AREA CODE (815) 725 - 4631		1.b. STREET ADDRESS(ES) AT WHICH RADIOACTIVE MATERIAL WILL BE USED (If different from 1.a.) INCLUDE ZIP CODE <div style="text-align: center;"> Same </div>			
2. PERSON TO CONTACT REGARDING THIS APPLICATION <div style="text-align: center;"> Gerald Wicks </div> TELEPHONE NO.: AREA CODE (312) 564 - 3330		3. THIS IS AN APPLICATION FOR: (Check appropriate item) a. <input type="checkbox"/> NEW LICENSE b. <input type="checkbox"/> AMENDMENT TO LICENSE NO. _____ c. <input checked="" type="checkbox"/> RENEWAL OF LICENSE NO. 12-18872-01			
4. INDIVIDUAL USERS (Name individuals who will use or directly supervise use of radioactive material. Complete Supplements A and B for each individual.) <div style="text-align: center;"> See Attachment for Item 4 </div>		5. RADIATION SAFETY OFFICER (RSO) (Name of person designated as radiation safety officer. If other than individual user, complete resume of training and experience as in Supplement A.) <div style="text-align: center;"> Jose Saban, M.D. </div>			
6.a. RADIOACTIVE MATERIAL FOR MEDICAL USE					
RADIOACTIVE MATERIAL LISTED IN:	ITEMS DESIRED "X"	MAXIMUM POSSESSION LIMITS (In millicuries)	ADDITIONAL ITEMS:	MARK ITEMS DESIRED "X"	MAXIMUM POSSESSION LIMITS (In millicuries)
10 CFR 31.11 FOR IN VITRO STUDIES			IODINE-131 AS IODIDE FOR TREATMENT OF HYPERTHYROIDISM		
10 CFR 35.100, SCHEDULE A, GROUP I	X	AS NEEDED	PHOSPHORUS-32 AS SOLUBLE PHOSPHATE FOR TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA AND BONE METASTASES		
10 CFR 35.100, SCHEDULE A, GROUP II	X	AS NEEDED	PHOSPHORUS-32 AS COLLOIDAL CHROMIC PHOSPHATE FOR INTRACAVITARY TREATMENT OF MALIGNANT EFFUSIONS.		
10 CFR 35.100, SCHEDULE A, GROUP III	X	3000	GOLD-198 AS COLLOID FOR INTRACAVITARY TREATMENT OF MALIGNANT EFFUSIONS.		
10 CFR 35.100, SCHEDULE A, GROUP IV	X	AS NEEDED	IODINE-131 AS IODIDE FOR TREATMENT OF THYROID CARCINOMA		
10 CFR 35.100, SCHEDULE A, GROUP V		AS NEEDED	XENON-133 AS GAS OR GAS IN SALINE FOR BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES.		
10 CFR 35.100, SCHEDULE A, GROUP VI					
6.b. RADIOACTIVE MATERIAL FOR USES NOT LISTED IN ITEM 6.a. (Sealed sources up to 3 mCi used for calibration and reference standards are authorized under Section 35.14(d), 10 CFR Part 35, and NEED NOT BE LISTED.)					
ELEMENT AND MASS NUMBER	CHEMICAL AND/OR PHYSICAL FORM	MAXIMUM NUMBER OF MILLICURIES OF EACH FORM	DESCRIBE PURPOSE OF USE		
Not Applicable 8506030663 850510 REG3 LIC30 12-18872-01 PDR			<div style="border: 1px solid black; padding: 5px;"> Applicant: <u>Feb 26</u> Check No. <u>5580</u> Amount: <u>70 Rev</u> Type of Fee: <u>2/27/85</u> Date Check Rec'd: <u>2/27/85</u> Received By: <u>[Signature]</u> </div>		
CONTROL NO. 78348					

INFORMATION REQUIRED FOR ITEMS 7 THROUGH 23

For Items 7 through 23, check the appropriate box(es) and submit a detailed description of all the requested information. Begin each item on a separate sheet. Identify the item number and the date of the application in the lower right corner of each page. If you indicate that an appendix to the medical licensing guide will be followed, do not submit the pages, but specify the revision number and date of the referenced guide: Regulatory Guide 10.8, Rev. _____ Date: _____

7. MEDICAL ISOTOPES COMMITTEE		15. GENERAL RULES FOR THE SAFE USE OF RADIOACTIVE MATERIAL (Check One)	
<input type="checkbox"/>	Names and Specialties Attached; and	<input type="checkbox"/>	Appendix G Rules Followed; or
<input type="checkbox"/>	Duties as in Appendix B; or _____ (Check One)	<input checked="" type="checkbox"/>	Equivalent Rules Attached
<input type="checkbox"/>	Equivalent Duties Attached	16. EMERGENCY PROCEDURES (Check One)	
8. TRAINING AND EXPERIENCE See attachment		<input type="checkbox"/>	Appendix H Procedures Followed; or
<input type="checkbox"/>	Supplements A & B Attached for Each Individual User; and	<input checked="" type="checkbox"/>	Equivalent Procedures Attached
<input type="checkbox"/>	Supplement A Attached for RSO.	17. AREA SURVEY PROCEDURES (Check One)	
9. INSTRUMENTATION (Check One)		<input type="checkbox"/>	Appendix I Procedures Followed; or
<input type="checkbox"/>	Appendix C Form Attached; or	<input checked="" type="checkbox"/>	Equivalent Procedures Attached
<input checked="" type="checkbox"/>	List by Name and Model Number	18. WASTE DISPOSAL (Check One)	
10. CALIBRATION OF INSTRUMENTS		<input type="checkbox"/>	Appendix J Form Attached; or
<input type="checkbox"/>	Appendix D Procedures Followed for Survey Instruments; or _____ (Check One)	<input checked="" type="checkbox"/>	Equivalent Information Attached
<input checked="" type="checkbox"/>	Equivalent Procedures Attached; and	19. THERAPEUTIC USE OF RADIOPHARMACEUTICALS (Check One)	
<input type="checkbox"/>	Appendix D Procedures Followed for Dose Calibrator; or _____ (Check One)	<input type="checkbox"/>	Appendix K Procedures Followed; or
<input checked="" type="checkbox"/>	Equivalent Procedures Attached	<input checked="" type="checkbox"/>	Equivalent Procedures Attached
11. FACILITIES AND EQUIPMENT		20. THERAPEUTIC USE OF SEALED SOURCES	
<input checked="" type="checkbox"/>	Description and Diagram Attached	<input type="checkbox"/>	Detailed Information Attached; and
12. PERSONNEL TRAINING PROGRAM		<input type="checkbox"/>	Appendix L Procedures Followed; or _____ (Check One)
<input checked="" type="checkbox"/>	Description of Training Attached	<input type="checkbox"/>	Equivalent Procedures Attached
13. PROCEDURES FOR ORDERING AND RECEIVING RADIOACTIVE MATERIAL		21. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE GASES (e.g., Xenon - 133)	
<input checked="" type="checkbox"/>	Detailed Information Attached	<input type="checkbox"/>	Detailed Information Attached
14. PROCEDURES FOR SAFELY OPENING PACKAGES CONTAINING RADIOACTIVE MATERIALS (Check One)		22. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE MATERIAL IN ANIMALS	
<input type="checkbox"/>	Appendix F Procedures Followed; or	<input type="checkbox"/>	Detailed Information Attached
<input checked="" type="checkbox"/>	Equivalent Procedures Attached	23. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE MATERIAL SPECIFIED IN ITEM 6.b	
<input type="checkbox"/>		<input type="checkbox"/>	Detailed Information Attached

24. PERSONNEL MONITORING DEVICES

TYPE <small>(Check appropriate box)</small>		SUPPLIER	EXCHANGE FREQUENCY
a. WHOLE BODY	<input checked="" type="checkbox"/> FILM	R. S. Landauer, Jr. & Co.	Monthly
	<input type="checkbox"/> TLD		
	<input type="checkbox"/> OTHER (Specify)		
b. FINGER	<input type="checkbox"/> FILM		
	<input checked="" type="checkbox"/> TLD	R. S. Landauer Jr. & Co.	Monthly
	<input type="checkbox"/> OTHER (Specify)		
c. WRIST	<input type="checkbox"/> FILM		
	<input type="checkbox"/> TLD		
	<input type="checkbox"/> OTHER (Specify)		

d. OTHER (Specify)

25. FOR PRIVATE PRACTICE APPLICANTS ONLY

a. HOSPITAL AGREEING TO ACCEPT PATIENTS CONTAINING RADIOACTIVE MATERIAL		b. ATTACH A COPY OF THE AGREEMENT LETTER SIGNED BY THE HOSPITAL ADMINISTRATOR.
NAME OF HOSPITAL St. Joseph Hospital	c. WHEN REQUESTING THERAPY PROCEDURES, ATTACH A COPY OF RADIATION SAFETY PRECAUTIONS TO BE TAKEN AND LIST AVAILABLE RADIATION DETECTION INSTRUMENTS.	
MAILING ADDRESS 333 North Madison Street		
CITY Joliet	STATE IL.	ZIP CODE 60435

26. CERTIFICATE

(This item must be completed by applicant)

The applicant and any official executing this certificate on behalf of the applicant named in Item 1a certify that this application is prepared in conformity with Title 10, Code of Federal Regulations, Parts 30 and 35, and that all information contained herein, including any supplements attached hereto, is true and correct to the best of our knowledge and belief.

a. LICENSE FEE REQUIRED <i>(See Section 170.31, 10 CFR 170)</i>	b. APPLICANT OR CERTIFYING OFFICIAL (Signature)
(1) LICENSE FEE CATEGORY 7c	(1) NAME (Type of Print) Jose Saban M.D.
(2) LICENSE FEE ENCLOSED \$ 580.00	(2) TITLE Director Diagnostic Imaging/Radiology
	c. DATE 2 / 15 / 85

PRIVACY ACT STATEMENT

Pursuant to 5 U.S.C. 552a(e)(3), enacted into law by section 3 of the Privacy Act of 1974 (Public Law 93-579), the following statement is furnished to individuals who supply information to the Nuclear Regulatory Commission on Form NRC-313M. This information is maintained in a system of records designated as NRC-3 and described at 40 Federal Register 45334 (October 1, 1975).

1. **AUTHORITY** Sections 81 and 161(b) of the Atomic Energy Act of 1954, as amended (42 U.S.C. 2111 and 2201(b)).
2. **PRINCIPAL PURPOSE(S)** The information is evaluated by the NRC staff pursuant to the criteria set forth in 10 CFR Parts 30-36 to determine whether the application meets the requirements of the Atomic Energy Act of 1954, as amended, and the Commission's regulations, for the issuance of a radioactive material license or amendment thereof.
3. **ROUTINE USES** The information may be used: (a) to provide records to State health departments for their information and use; and (b) to provide information to Federal, State, and local health officials and other persons in the event of incident or exposure, for their information, investigation, and protection of the public health and safety. The information may also be disclosed to appropriate Federal, State, and local agencies in the event that the information indicates a violation or potential violation of law and in the course of an administrative or judicial proceeding. In addition, this information may be transferred to an appropriate Federal, State, or local agency to the extent relevant and necessary for a NRC decision or to an appropriate Federal agency to the extent relevant and necessary for that agency's decision about you. A copy of the license issued will routinely be placed in the NRC's Public Document Room, 1717 H Street, N.W., Washington, D.C.
4. **WHETHER DISCLOSURE IS MANDATORY OR VOLUNTARY AND EFFECT ON INDIVIDUAL OF NOT PROVIDING INFORMATION** Disclosure of the requested information is voluntary. If the requested information is not furnished, however, the application for radioactive material license, or amendment thereof, will not be processed.
5. **SYSTEM MANAGER(S) AND ADDRESS** Director, Division of Fuel Cycle and Material Safety, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555.

ITEM 4 and 8

AUTHORIZED USERS - TRAINING AND EXPERIENCE

NAME

Jose Saban, M.D.

TRAINING AND EXPERIENCE

NRC License No. 12-18872-01

INSTRUMENTATION

1. SURVEY METER

A. Manufacturer: Victoreen *
B. Model Number: 498
C. Number of Instruments Available: One
D. Minimum Range: 0-1 mR/hr
E. Maximum Range: 0-1 R/hr

2. DOSE CALIBRATOR

A. Manufacturer: Rad Cal II
B. Model Number: 34-061
C. Number of Instruments Available: One

3. DIAGNOSTIC INSTRUMENTS

A. Type of Instrument: Scintillation Camera
B. Manufacturer: Picker
C. Model Number: Dyna Camera

- * In the event that we acquire our radiopharmaceuticals in unit doses from a local radiopharmacy, we may have a substitute survey meter such as the Victoreen CDV-700 with a minimum range of 0 to 0.5 mR/hr and a maximum range of 0 to 50 mR/hr.

CONTROL NO. 48348

CALIBRATION OF INSTRUMENTS

Methods, Frequency, Standards

SURVEY INSTRUMENTS:

Calibration and repair of survey instruments will be done annually by Health Physics Associates, Ltd., 3304 Commercial Avenue, Northbrook, Illinois 60062.

The procedure used to calibrate survey meters is on file with the Nuclear Regulatory Commission, under Health Physics Associates Ltd.'s license No. 12-09160-01. When a survey meter is sent for repair or calibration, a "loaner" survey meter will be supplied by Health Physics Associates, Ltd.

Cs-137 reference standard will be used to check the constancy of the GM survey meter prior to use. If a reading with the same geometry is not within $\pm 20\%$ of the reading measured after calibration, the instrument will be recalibrated.

DOSE CALIBRATOR:

The following checks will be performed on the dose calibrator:

- A. Constancy - Daily
- B. Linearity - Quarterly
- C. Accuracy - Annually
- D. Geometrical Variation - At installation and after chamber replacement

A. Constancy

A Cs-137 standard, consisting approximately 200 μCi of activity will be assayed in the dose calibrator daily in the Cs-137 setting on the instrument. The standard used will be traceable to the National Bureau of Standards. The dose calibrator initial assay of the standard should not differ by more than $\pm 5\%$ from the anticipated range of activity of the standard.

The Cs-137 source will be assayed daily in other radionuclide settings routinely used in the department. The assay of the sources will not vary by more than $\pm 5\%$ from week to week. Once a week, the Cs-137 source will be assayed in other radionuclide settings occasionally used in the department and the readings should not vary by more than $\pm 5\%$ from week to week.

B. Linearity will be performed using one of the following two methods

- 1) The linearity of the instrument will be established quarterly. The procedure employed will be such that it will cover the entire range of activity that the department may use. The maximum quantity of radioactivity that we may have on hand in a single container would be elution from Mo99/Tc99m generator (Tc99m pertechnetate).

Knowing the volume in the vial, the concentration of the activity can be calculated. One milliliter of eluent is drawn precisely into a syringe and it is assayed in the dose calibrator. The reading should be within $\pm 5\%$ to be acceptable.

Further linearity will be determined as follows: The same syringe is then further assayed at approximately 6 hours, 24 hours, 30 hours and 48 hours after the activity was drawn into the syringe. For acceptable linearity, all the assay results must be within $\pm 5\%$ of the calculated values.

- 2] We may use the "Calicheck Kit" from Calcorp, Inc., P.O. Box 25589, Cleveland, Ohio 44125-0589. A copy of the brochure is attached. The initial linearity of the dose calibrator will be confirmed using the decay method as indicated above. The "Calicheck Kit" will be used according to the instructions from the supplier of the kit.

C. Accuracy

The accuracy of the dose calibrator at various energy levels will be confirmed at installation, after repairs, and once a year thereafter, using three reference standards whose activity is traceable to the National Bureau of Standards. These standards are obtained from New England Nuclear.

RADIONUCLIDE	CATALOG No.	APPROXIMATE ACTIVITY	SOURCE TYPE
Cs-137	NES-356	200 μ Ci	Vial E
Ba-133	NES-358	250 μ Ci	Vial E
Co-57	NES-206	5.0 mCi	Vial E

Each standard will be assayed in the appropriate settings three times and the average of the three settings will be calculated. After subtracting the room backgrounds, the average source assay should be within $\pm 5\%$ of the anticipated range of activity of each source. The sources are possessed by IML Imaging Inc., for the specific purpose of annual calibration of the dose calibrator. The sources will not be stored on site at the hospital.

D. Geometrical Variation - At Installation and After Chamber Replacement

As explained in paragraph "B" above, the geometrical independence between the vial and the syringe is first established. The activity in the syringe is then further diluted 0.5 ml at a time, mixed properly, and the syringe assayed after every step. In this manner, a series of readings of the same activity in different volumes are obtained. If the assay result in any volume is above $\pm 2\%$ of the mean value, a corrective value will be determined.

Similarly, a 20 mCi activity in a vial is assayed in different volumes and correction factors computed when necessary.

E. Acceptable Performance

If a dose calibrator does not meet the specifications in sub-items A-D above, replacement dose calibrator will be obtained while the instrument is shipped for repairs.

Patient Doses

All patient doses will be assayed prior to administration to ensure that they are within $\pm 10\%$ of the prescribed dose.




**Now meet governmental
regs in 4 minutes
...not days!**



Fast

Now with the newly developed Calichek™ dose calibrator activity linearity test kit†, you can meet N.R.C. Regulatory Guide 10.8, appendix D, Section 2E or your state's equivalent requirement in just 4 minutes — not days.* You can complete the test in one short sitting and check for linearity virtually at a glance. Plus you eliminate the frustration of having to start the test all over simply because you forgot to take a reading on time. † (Patent pending)



Accurate and Reliable

The new Calichek kit is designed to attenuate radiation by known values — accurate using a high yield generator eluant or a unit dose.

A Calichek kit provides for seven successive measurements simulating the decay of ^{99m}Tc at approximately 0, 6, 12, 21, 31, 41 and 51 hours from the initial assay.



Complete Yet Reusable

Your Calichek kit comes to you complete with its own storage container, a

unique arrangement of seven color-coded lead-wrapped tubes, work/record keeping sheets, instructions for use including specific correction factors, and a license amendment form (if needed.)

Your Calichek kit is completely reusable for an indefinite period of time. There is nothing to wear out or use up. If damage should cause a tube to malfunction, individual replacements are available.



Safe

Your use of a Calichek kit eliminates the need to fractionate eluants or decay the elution for several days while periodically collecting data to determine linearity. Time of potential exposure to radiation is drastically reduced, thereby maintaining exposures ALARA.



Lowers Department Costs

When you test with a Calichek kit, both the source activity and dose calibrator can be returned to active service in just minutes. This savings alone can pay for a Calichek kit in just three to four linearity tests. A Calichek kit lets you return to active service too!



Can Improve Patient Care


A Calichek kit is so fast, efficient and easy to use, you may wish to check dose calibrator linearity more frequently. Lets you spot trouble before it becomes serious.



Low Price

A Calichek dose calibrator activity linearity test kit is just \$325.00 shipping included.

Just complete and return the card with your check or call (216) 663-1773.



As simple as 1, 2, 3, 4, 5, 6, 7. Place red central tube in dose calibrator. Place source in red tube and take a reading. Then sequentially place color-coded tubes over red tube. Additional readings are taken immediately, converted with a given factor and you can see the degree of linearity virtually at a glance.



*As presented in a scientific paper before the 28th Annual Meeting of the Society of Nuclear Medicine, 1981, Las Vegas, Nevada.

CALCORP, INC.
P.O. Box 25589
Cleveland, Ohio 44125-0589
Phone No. (216) 663-1773

Item #10

CONTROL NO. 78348

(2/85)

DOSE CALIBRATOR MAKE & MODEL # _____

CALIBRATOR SOURCE _____ ACTIVITY _____ DATE _____ S/N _____

[illegible]


ITEM 11 - DESCRIPTION OF FACILITIES

The Nuclear Medicine Department is located in the basement of the building. The surrounding facilities are indicated in the attached diagram.

All radioactive materials are used in the hot lab and imaging room. All radioactive materials are stored in the hot lab. (Please refer to Item 13 regarding the receipt of radioactive materials.)

The outside stairway door, door at the base of the stairway, lead safe at the base of the stairway, Nuclear Medicine Department and hot lab doors are all lockable.

Nuclear Medicine Dept.
Glenwood Medical Center
2000 Glenwood Ave.
Joliet, IL



A - Vented Storage Area

B - Generator (shielded by 2"x4"x8" lead bricks)

C - Dose Preparation Area (L-Block Available)

D - Dose Calibrator

E - Under Counter Top Waste Storage

F - Secured Door

G - Xenon Ventilation System

H - Secured Door

I - Air Supply

J - Air Exhaust

K - Console

L - Scanning Table CONTROL NO. 78348

M - Detector Head

N - Secured Door

O - Lockable Lead Safe (0.6cm lead lining)

P - Secured Door To Outside

ITEM II

(2/85)

PERSONNEL TRAINING PROGRAM

In accordance with NRC Regulations, instructions to workers will be carried out in the following manner:

1. All individuals working in or frequenting any portion of a restricted area shall be kept informed of the storage, transfer or use of radioactive materials or of radiation in such portions of the restricted area.
2. All individuals working in or frequenting any portion of a restricted area shall be instructed in the health protection problems associated with exposure to such radioactive materials, in precautions or procedures to minimize exposure, and in the processes and functions of protective devices employed.
3. All individuals working in or frequenting any portion of a restricted area shall be instructed in, and instructed to observe, to the extent within the worker's control, the applicable provisions of the Commission to radiation or radioactive materials occurring in such areas.
4. All individuals working in or frequenting any portion of a restricted area shall be instructed of their responsibility to report promptly to the licensee, any conditions which may lead to or cause a violation of Commission Regulations and Licensee of unnecessary exposure to radiation or to radioactive material.
5. All individuals working in or frequenting any portion of a restricted area shall be instructed in the appropriate response to warnings made in the event of any unusual occurrence or malfunction that may involve exposure to radiation or radioactive material.

The Nuclear Medicine Technologist will be classified as occupational employees. These individuals perform their duties from the radiation safety viewpoint under the direction of the physician at the hospital named on the license application.

Every effort will be made to find technologists educated in Nuclear Medicine Technology in an institution approved by the American Medical Association. Such employees will be certified or eligible for certification in Nuclear Medicine Technology and for licensure by IDNS. Orientation of radiation safety and techniques of such personnel, for one or two days by the Radiation Safety Officer, will be considered sufficient.

All Nuclear Medicine Technologists will be instructed before assuming duties and annually thereafter by the Radiation Safety Officer or the Chief Technologist in the following areas:

- (a) New procedures and radiopharmaceuticals in Nuclear Medicine
- (b) Radiation Safety Techniques
- (c) NRC and State Rules and Regulations for the use of radioactive materials.
- (d) Location of regulations, license, license applications, regulatory notices and dosimetry and bioassay reports. All of these documents and reports are available for employee inspection upon request to the R.S.O.

With regard to non-occupational personnel at hospitals and their contact with the Nuclear Medicine Department, the Staff Technologist will be instructed to restrict access to the department to those people having business there.

NON-OCCUPATIONAL PERSONNEL WHEN REQUIRED TO ASSIST THE TECHNOLOGIST WITH A PATIENT, WILL NEVER BE ALLOWED TO HANDLE ANY RADIOACTIVE MATERIAL.

Any person requested to assist with a patient will do so under the direction of the Nuclear Medicine Technologist who will ensure that the exposure to these persons is held to a minimum (through time, distance and shielding) during the performance of the Nuclear Medicine procedure.

A short "orientation" program will be conducted annually for the non-occupational personnel such as security, clerical, housekeeping, etc., who may be involved in Nuclear Medicine Department functions where radioactive materials are stored or used. The orientation will include:

- (a) Tour of the Department to indicate the radioactive material storage space(s), location of the 10 CFR Parts 19, 20, 30, 31 and 35, location of the survey meter, etc.
- (b) Concepts of radiation safety - distance, time, shielding.
- (c) Names and phone numbers of person(s) to contact in case of a radiation emergency.

If a new, non-occupational employee is involved in Nuclear Medicine Department functions, the employee will be given a short orientation program before the employee begins duties in the Nuclear Medicine Department.

- (d) The radioactive material, if used (injected) in our Cardiac Stress Lab for Tl-201 stress studies, the access to the stress unit will be limited to the physician, the stress lab technologist(s) and the patient during the use of Tl-201. The stress lab technologists will be given a copy of "Emergency Procedures for Minor Spills" for posting in the stress unit room.

ITEM 13 - PROCEDURES FOR ORDERING AND RECEIPT OF RADIOACTIVE MATERIAL

A. ORDERING

Radiopharmaceuticals will be ordered from suppliers licensed by the NRC or State according to 10CFR32 or Agreement State Regulations. Ordering will be initiated by the Nuclear Medicine Technologist who will insure the inventory is adequate for planned and anticipated procedures, but not in excess of possession limits where applicable.

B. RECEIVING

1. During Working Hours -

Instructions will be issued to the carrier delivering radiopharmaceuticals to effect delivery directly to the Nuclear Medicine Department. Radiopharmaceutical packages are not to be left unattended in the unrestricted areas. The nuclear medicine technologist will sign the delivery receipt.

2. During Off Duty Hours -

Instruction will be issued to the carrier delivering the radiopharmaceuticals, to leave the package in the lead safe at the base of the stairwell near the Nuclear Medicine Department. (See diagram in Item 11 attached for location of lead safe.) The lead safe will be locked after deposition of the radioactive package in the lead safe by the carrier.

The carrier has keys to the outside stairwell door and to the lead safe only. Nuclear Medicine personnel have keys to the lead safe and to the Nuclear Medicine Department

The lead safe is 18" X 18" with a 0.6 cm lead lining.

ITEM 13

CONTROL NO. 78348

(2/85)

(6/84)

GLENWOOD MEDICAL GROUP

2000 GLENWOOD AVENUE
JOLIET, ILLINOIS 60435

(815) 725-4631

SURGERY

NOEL M. BASS, M.D., F.A.C.S.
WILLIAM A. SIMS, M.D., F.A.C.S.
JON F. NICOSIA, M.D., F.A.C.S.
ROBERT T. CHAMBERS, M.D., F.A.C.S.

ORTHOPEDIC SURGERY

NADINE SCHMITZ, M.D.

GENERAL PRACTICE

RONALD VAN ARSDELL, M.D.
BRUCE J. WALLIN, M.D. - EMERITUS
RAYMOND G. ORENIC, M.D.
JOSEPH A. ZALAR, M.D. - EMERITUS
WILLIAM STAPLETON, M.D.

INTERNAL MEDICINE

WARREN WUNDERLICH, M.D.
DEBORAH FREEMAN, M.D.

NEUROLOGY

SETH WHARTON, M.D.

OBSTETRICS - GYNECOLOGY

F. PATRICK MC QUILLAN, M.D.
F.A.C.O.G., F.A.C.S.
GARY HAUKE, M.D.

PEDIATRICS

LORENZO ASCHINBERG, M.D.
F.A.A.P.
DZINTRA GREENWALD, M.D.
F.A.A.P.
MARGARET TIPPLE, M.D.
GILDA ALCALA, M.D.

RADIOLOGY

JOSE SABAN, M.D.

ADMINISTRATION

RICHARD M. FINN

TO: DEPARTMENT HEAD OF:

Security
Purchasing
Receiving
Switchboard
Emergency Room
Radiology
Nuclear Medicine

FROM: ADMINISTRATOR

SUBJECT: RECEIPT OF PACKAGES CONTAINING RADIOACTIVE
MATERIALS BEARING WHITE I, YELLOW II OR III,
HAZARDOUS MATERIAL

1. During hours in which the Nuclear Medicine Department is open, all couriers or common carriers requesting assistance in delivering packages containing radioactive materials are to be directed to the Nuclear Medicine Department. Personnel, except for those in the Nuclear Medicine Department, are not to accept the package or handle the package personally.
2. If couriers or common carriers attempt delivery of packages containing radioactive materials during those hours in which the Nuclear Medicine Department is closed, the package must be placed in the lead safe at the base of the adjacent stairwell to Nuclear Medicine and locked by the Carrier.
3. If the package is wet or appears to be damaged, immediately contact the Radiation Safety Officer. The carrier will be notified if the package is contaminated by the Radiation Safety Officer.

RADIATION SAFETY OFFICER: Jose Saban, M.D.

ROUTINE WORK HOURS: CALL: X-RAY

AFTER WORK HOURS: CALL: "OPERATOR"

PROCEDURE FOR SAFELY OPENING PACKAGES CONTAINING RADIOACTIVE MATERIAL

1. Wear gloves during package inspection and opening to prevent contamination.
2. Inspect and open all packages **IMMEDIATELY** upon receipt. Should package arrive when the Nuclear Medicine Department is closed, this procedure will receive top priority as soon as the Nuclear Medicine personnel returns. If visual inspection shows any signs of damage (if wet or crushed, etc.) stop procedure and notify the Radiation Safety Officer.
3. All radioactive packages will be surveyed at surface and at three feet to verify that the radiation levels on the surface of the package are not in excess of 200 millirems per hour, or at three feet from the external surface of the package in excess of 10 millirems per hour. If the levels are in excess of the ones indicated above, the NRC Region III will be notified by telephone.
4. Open package, remove packing slip and verify that the contents agree in name and quantity with the packing slip. Check also that shipment does not exceed possession limits.
5. If a wipe test of the package is required to be done as specified in 10CFR20.205, the wipe will be performed and analyzed as instructed in "Wipe Test Procedure" which follows.
6. Check the possible breakage of seals or container's loss of liquid or change in color of absorbing material. Wipe test the final source container to rule out contamination. (For wipe test procedure, refer to next page.)
7. Place the radioactive source in its shield and store in the Isotope Storage Area.
8. Monitor the shipment packing material for contamination after removal of the sources. Deface labels and discard.
9. Record type of activity, quantity present, date of receipt and invoice number on the radiopharmaceutical inventory form (attached).
10. If the material was packaged in dry ice, refrigerate immediately.
11. If excessive radiation levels, contamination, leakage or shortages are observed, notify the final delivering carrier and by telephone or telegraph contact the Regional Office of the Nuclear Regulatory Commission. Also notify the Radiation Safety Officer of any damage or leakage resulting in contamination.

ITEM 14

WIPE TEST PROCEDURE

1. To be performed on all shipments, specified in Part 10CFR20.205, and on final containers of all radioactive sources.
2. To be performed as soon as practicable after receipt. If recieved during working hours, wipe test must be performed within three (3) hours; if received at some other time, within eighteen (18) hours after receipt.
3. PROCEDURE -
 - a] Wipe the surface of the container over its entirety with an alcohol swab.
 - b] Check the wipe using a low level GM survey meter probe with window open. The wipe should be centered on the open window of the probe and held as close as possible to the probe, but not in contact with the probe, for approximately 10 to 15 seconds. Record the reading in mR/hr.

If the radiation level is higher than the natural background levels in an unrestricted area, a scintillation camera detector without collimator will be used to determine the level of contamination.

ITEM 14

CONTROL NO. 78348

USE OF Mo99/Tc99m GENERATOR

The Mo99/Tc99m generator will be eluted according to the instructions described in the package insert from the radio-pharmaceutical company. This will provide an eluent of pharmaceutical quality.

99mTc and 99Mo assay of the eluted material from the generator will be performed after each elution according to the instructions described in the package insert from the radio-pharmaceutical company. The assay, along with the assay of compounds synthesized from technetium eluates, will be accomplished through the use of a dose calibrator device. When the dose calibrator is sent away for repairs, a "loaner" will be obtained.

The purity of the eluted material will be determined by the above assay. The eluted sources containing more than 1.0 uCi of 99Mo per millicurie of 99mTc or final patient dose containing more than 5.0 uCi of 99Mo, will not be used directly or in compounding.

Compounds formulated using kits and technetium from the above generator will be prepared by following the kit manufacturer's directions, exactly as outlined in the package insert. No alterations or substitutions will be permitted. In this way a product of pharmaceutical quality will be insured. Syringe shields and lead containers for vials will be used during formulation of these compounds.

All patient doses will be assayed with a dose calibrator to assure that the dose is within $\pm 10\%$ of the prescribed dose.

GENERAL RULES AND SAFE USE OF RADIOACTIVE MATERIAL

1. Wear laboratory coat or other protective clothing at all times in areas where radioactive materials are used.
2. Wear disposable gloves while handling radioactive materials.
3. Monitor hands and clothing if contamination is suspected after handling radioactivity.
4. Always use syringe shields for routine preparation of patient doses and administration to patients, except in circumstances such as pediatric cases when their use would compromise the patient's well-being. In these exceptional cases, use other protective methods such as remote delivery of the dose (e.g. through use of a butterfly valve).
5. Do not eat, drink, smoke or apply cosmetics in any area where radioactive material is stored or used.

Do not store food, drink or personal effects with radioactive material.
6. Assay each patient dose in the dose calibrator prior to administration. Do not use any doses that differ from the prescribed dose by more than 10%.

For therapeutic doses, also check the patient's name, the radionuclide, the chemical form, and the activity vs. the order written by the physician who will perform the procedure.
7. Wear personnel monitoring devices (film badge or TLD) at all times while in areas where radioactive materials are used or stored. These devices should be worn at chest or waist level. Personnel monitoring devices, when not being worn to monitor occupational exposures, should be stored in a designated, low background area.
8. Wear TLD finger badges during elution of generator and preparation assay and injection of radiopharmaceuticals.
9. Dispose of radioactive waste only in specially designated and properly shielded receptacles.
10. Never pipette by mouth.
11. Survey generator, kit preparation, and injection areas for contamination at the end of the day. Decontaminate if necessary.

12. Confine radioactive solutions in covered containers plainly identified and labeled with name of compound, radionuclide, date, activity and radiation level, if applicable.
13. Always transport radioactive material in shielded containers.
14. Mo99/Tc99m generator eluent will be assayed to determine Mo99 concentration and the eluent will not be used if Mo99 concentration is equal to or exceeds 1 uCi Mo99 per 1 mCi of Tc99m; or if a dose contains more than 5 uCi of Mo99.

ITEM #15

CONTROL NO. 78848

(2/85)

RADIOPHARMACEUTICAL INVENTORY

DATE RECEIVED / / RADIATION LEVELS (mR/hr): SURFACE 3 FT EMPTY INITIALS

WIPE: mR/hr

PLACE LABEL
HERE

PLACE LABEL
HERE

PLACE LABEL
HERE

ACT. ADM. mCi TIME
INITIALS

ACT. ADM. mCi TIME
INITIALS

ACT. ADM. mCi TIME
INITIALS

PLACE LABEL
HERE

PLACE LABEL
HERE

PLACE LABEL
HERE

ACT. ADM. mCi TIME
INITIALS

ACT. ADM. mCi TIME
INITIALS

ACT. ADM. mCi TIME
INITIALS

All used syringes, needles, & unused doses above, returned to supplier. DATE

INITIALS

(2/85)

RADIOPHARMACEUTICAL INVENTORY

HOSPITAL:

DATE RECEIVED:		RADIATION LEVEL mR/hr		Wipe Surface 3 Ft. Empty Wipe		Date or Time	Patient Name	Patient #	Concentration mCi/ml	Activity administered mCi	Volume administered ml	Volume remaining ml	Activity remaining mCi
RADIOPHARM:													
MANUFACTURER:													
LOT #													
DATE RECEIVED:													
RADIOPHARM:													
MANUFACTURER:													
LOT #													
DATE RECEIVED:													
RADIOPHARM:													
MANUFACTURER:													
LOT #													

EMERGENCY PROCEDURES FOR RADIOACTIVE SPILLS

Unsealed radioactive liquids are handled routinely in the Nuclear Medicine Department. The potential for spillage is always present. It is imperative that individuals handling radioactive materials respond properly to these spills so as to limit their radiation exposure and prevent the spread of contamination.

MINOR SPILLS: (tracer activities)

1. Notify persons in the immediate area that a spill has occurred.
2. Cover the spill with absorbent paper.
3. Limit access to area to only those persons dealing with the spill.
4. Survey (GM survey meter) potentially contaminated personnel before they disperse; and decontaminate as necessary.
5. Notify the Radiation Safety Officer of the incident.

MAJOR SPILLS: (therapy activities)

1. Notify all persons not involved in the spill to vacate the room at once. Limit the movement of displaced persons to confine the spread of contamination.
2. Cover spill with absorbent paper.
3. Switch off all fans. Close windows.
4. Vacate room.
5. Close the door to the room. Prevent entry into the room.
6. If the spill is on the skin, flush thoroughly.
7. If the spill is on the clothing, discard outer or protective clothing at once.
8. Notify the Radiation Safety Officer immediately.
9. Survey (GM survey meter) personnel involved. Immediately initiate decontamination of personnel as necessary, using mild soap and luke warm water.

CONTROL NO. 17148

FIRE AND / OR EXPLOSIONS

1. In the event of fire, explosion or similar catastrophe, the emergency within the hospital must be given attention first. Patients must be immediately cared for.
2. Should the catastrophe occur within the Department of Nuclear Medicine, vacate the area and all surrounding areas immediately.

HOWEVER, DO NOT LET THE LOCATION OF OCCURRENCE PREVENT ADEQUATE AND IMMEDIATE PATIENT PROTECTION.

3. Block off the area with ropes, chairs or whatever is available until such time as fire or other emergency personnel arrive.
4. Notify the Radiation Safety Officer immediately.
5. Monitor area to determine extent of contamination.
6. Take necessary steps to decontaminate the area according to instructions of the Radiation Safety Officer.

LOSS OR THEFT OF RADIOACTIVE MATERIALS OR DAMAGE TO A RADIOACTIVE SOURCE

If the radioactive source is damaged, the precaution to prevent the spread of the contamination will be taken. The area concerned will be decontaminated and the damaged source will be stored in adequate shielding.

If a source is lost or stolen, the Radiation Safety Officer and the U.S. Nuclear Regulatory Commission or the appropriate State authorities will be notified.

If a source is involved in a fire and/or explosion and if a source is damaged, the appropriate State authorities will be notified.

Illinois Department of Nuclear Safety	(217) 782 - 7860
U.S. Nuclear Regulatory Commission	(312) 790 - 5500

ITEM #16

AREA SURVEY PROCEDURES

1. All elution, preparation and injection areas will be surveyed daily with a GM survey meter and decontaminated if necessary. Results will be recorded on the form attached: "DAILY RADIATION SAFETY RECORD".
2. Laboratory areas where only small quantities of radioactive material are used (less than 200 μ Ci) will be surveyed monthly.
3. All the areas in the Nuclear Medicine Department will be surveyed once a week using a low-level GM survey meter. Results will be recorded. The areas surveyed are:
 - A. Dose Preparation Area
 - B. Generator
 - C. Radioactive Material Storage
 - D. Radioactive Material Waste Storage
 - E. Floor Near the Dose Prep Area
 - F. Tl-201 Stress Unit (if Tl-201 is used during the week)
 - G. Injection Area
 - H. Refrigerator
 - I. Sink and Trap
 - J. Imaging Room
4. Wipe tests of areas (listed above) A-E, and F if used during the week, and injection areas will be taken once a week. The wipe will be checked in an unrestricted area (natural background radiation levels) using a low level GM survey meter with the window on the probe open. The wipe will be held for approximately 20 seconds as close to the probe as possible, without actually touching the probe.

If the wipe indicates radiation levels above those of natural background in unrestricted areas (0.1 mR/hr or less), the area will either be secured and/or decontaminated until a wipe indicates natural background radiation levels.

We have found in our experience that a wipe test of an area is essential when attempting to detect contamination near a radioactive container such as near an Mo99/Tc99m generator. If a GM survey is done, it would be impossible to differentiate between the radiation levels from the source and the radiation levels from contamination in the proximity of the source. But a wipe of the area can be analyzed in an unrestricted area, away from any source of radiation (other than natural background). Hence, the generator area and the dose preparation area (where sources emitting radiation, easily detectable by a GM survey meter, may be stored) would be wipe tested once a week. Any contamination in the other areas in the department would be easily detected by a low level GM survey meter and hence, a wipe test would not be necessary.

YEAR	HOSPITAL
------	----------

Record levels in mR/hr.

NATURAL BACKGROUND RADIATION LEVELS ARE: mR/hr

[illegible]

Mo99/Tc99m GENERATOR

RADIOACTIVE WASTE, STORAGE AND DISPOSAL

Radioactive waste storage and disposal can be broken down into three categories:

1. Molybdenum-99 Technetium-99m generators
2. Technetium 99m residues
3. "Long-lived" radionuclides: radionuclides with relatively longer (greater than six hours) half-life such as Selenium-75, I-131, etc.

1. Mo99m/Tc99m GENERATOR DISPOSAL

- A. The current Mo/Tc99m generator used for daily elution will be stored behind the lead bricks in the hot lab. Generator systems, one week old and older, can be safely stored in their original lead shipping containers for the balance of the decay necessary to reduce levels from the generator core to those of background.

It is estimated that Mo99/Tc99m generators will be decayed for approximately two months from the date of assay; that is, about 25 half-lives. The generator core will be monitored with a low level GM survey meter and, upon reaching background level, will either be incinerated or the labels defaced and discarded.

- B. In the event a return program is initiated, the generator may be sent to the supplier intact according to directions received with shipment. The date of the disposal will be recorded on the "RADIOPHARMACEUTICAL INVENTORY FORM". If returned to the supplier, the date will be recorded.

2. Tc99m COMPOUNDS

Ninety percent or more of the radioactivity used in this hospital will be associated with the use of Tc99m in its various chemical forms.

Tc99m sources and residues, i.e. contaminated syringes, needles, vials of unused Tc99m preparation and Tc99m eluents, will be stored in a plastic bag behind the lead bricks. At the beginning of the following week, the plastic bag containing the Tc99m contaminated sources will be sealed and held in the Nuclear Medicine Department behind lead shielding. At the end of the week, the contents of the plastic bag containing the decayed compounds (every item in the bag now has been decayed for a minimum of seven days, 24 half-lives) will be brought out from their lead shielding.

The low level survey meter probe will be brought into contact with the unshielded vials and/or syringes. If the meter needle does not deflect above background levels, these formerly contaminated items will be discarded, after defacing or removing the "radioactive" labels. The date of disposal and the survey meter reading indicating background levels will be recorded on the isotope disposition form.

3. UNIT DOSE FROM A RADIOPHARMACY

All used syringes, needles and unused doses will either be stored for decay or will be returned to the radiopharmacy in containers in which the doses were received. A representative from the radiopharmacy will pick up the containers from the hospital. Records of such disposal will be maintained. Applicable Department of Transportation Regulations will be followed.

4. "LONGER HALF-LIFE RADIONUCLIDES"

Radionuclides having half-lives up to and including I-131:

Such nuclides and their residues will be stored behind lead bricks. A survey will be conducted with the probe held against the unshielded source. After a period of decay of from one to three months, depending upon the nuclide's half-life, levels as measured with the lowest range on the GM survey meter in excess of background will indicate the need for a continuing period of decay. Finding levels the same as that of background will result in discarding these sources.

CONTROL NO. 78348

ITEM #18

Radionuclides having half-lives in excess of I-131 will be diluted via the sewer as early as convenient (in compliance with 10 CFR 20.303).

A measurement of the quantity of radioactivity will be made using the dose calibrator prior to disposing of the radioactivity down the drain. Syringes, needles and vials contaminated with such radionuclides will then be rinsed three or four times and then they will be surveyed unshielded in contact with a low level GM survey meter prior to disposal.

If levels in excess of background are noted, the contaminated articles will be further rinsed until background levels are achieved. In-vitro test wastes in the laboratory will be recorded as 100% sewer-diluted, based on receipt quantity. No measurement with the dose calibrator will be made. The date and quantity of radioactivity sewer-diluted, will be entered on the isotope disposition form. To comply with 10 CFR 20.303(b), a sample calculation for Se-75 is attached. Similar procedures will be followed for other radionuclides.

To comply with 10 CFR 20.203(d), a separate record of all types of activity sewer-diluted by this institution will also be maintained to ensure that the gross quantity of licensed and other radioactive material released into the sewer system does not exceed one curie per year.

Calculation for the quantity of Se-75 which can be sewer-diluted daily:

As specified in 10 CFR 20.303(b)(1), the average concentration for Se-75 as give in Appendix B, Table 1, Column 2, is 9×10^{-3} uCi/ml.

Quantity of Se-75 which can be sewer-diluted:

$$\begin{aligned} &= \text{number of beds occupied} \times 10^6 \times \text{Appendix B,} \\ &\quad \text{Table 1, Column 2, limits for Se-75} \\ &= 100 \times 10^6 \times 9 \times 10^{-3} \text{ uCi/day} \\ &= 900 \times 10^3 \text{ uCi/day} \\ &= 900 \text{ mCi/day} \end{aligned}$$

The total quantity of all types of radioactivity sewer-diluted is not to exceed 1000 mCi/year.

RADIOACTIVE WASTE DISPOSAL RECORDS

[illegible]

FOR TREATMENT OF PATIENTS (I-131 THERAPY)

1. Ordering and Handling I-131 Therapy Dose

A. Ordering:

The I-131 therapy dose will be ordered when possible, in capsule form, and will be delivered on the morning of the day the therapy is scheduled.

B. Upon receipt of the therapy dose package, it will be monitored in accordance with conditions of the NRC license.

C. The source will then be stored, in its lead shielding, in the radiopharmaceutical storage area until the time of administering therapy.

D. If the I-131 is obtained in a liquid form:

(i) The stopper of the vial containing the therapy dose will be opened in the fume hood with the fume hood blower operating.

(ii) The liquid dose will be administered orally, directly from the shielded vial, using a straw and the vial will be rinsed several times, each time the patient drinking the contents.

(iii) The "empty" vial will be decayed in storage in accordance with conditions of our license.

(iv) 24 hour thyroid uptake will be performed on the technologist involved in handling the liquid therapeutic dose.

2. Patients requiring hospitalization and treated with 8 mCi or more of I-131 will be placed in a private room with a toilet, or a semi-private room without another patient.

3. The patient's room will be properly posted in accordance with section 20.203, 10 CFR Part 20.

4. Surveys of the patient's room and surrounding areas will be conducted as soon as practicable after administration of the treatment dose. Exposure rates will be measured at the patient's bedside, three feet away, and the entrance to the room.

The Radiation Safety Officer or his designate, will then determine how long a person may remain at these positions and will post these items in the patient's chart and on the door. The results of daily surveys will be used to recalculate permitted times which will be posted on the patient's chart and on his door.

5. The form, "NURSING INSTRUCTIONS FOR PATIENTS TREATED WITH I-131", will be completed immediately after administration of the treatment dose. A copy will be posted on the patient's chart.
6. Radiation levels in unrestricted areas will be maintained less than the limits specified in Section 20.105(b), 10 CFR Part 20.
7. All linens will be surveyed for contamination before being removed from the patient's room and will, if necessary, be held for decay.
8. Disposable plates, cups, eating utensils, tissue, and other similar waste items will be placed in a specially designated container. The material will be collected daily by the Radiation Safety Officer (or his designate), checked for contamination, and disposed of as normal for radioactive waste, as appropriate.
9. Non-disposable items used for these patients will be held in plastic bags in the patient's room and checked for contamination by the Radiation Safety Officer (or his designate). Items may be returned for normal use, held for decay, or decontaminated as appropriate.
10. The patient's urine will not be collected. The patient will be instructed to use the toilet and flush the toilet at least three times after each use.
11. Before a therapy patient's room is reassigned to another patient, the room will be surveyed for contamination and decontaminated if necessary. All radioactive waste and waste containers will be removed.

ITEM #19

(2/85)

NURSING INSTRUCTIONS

1. Nurses should spend only that amount of time near the patient required for ordinary nursing care. Special restrictions may be noted on the precaution sheet on the patient's care. Nurses should read these instructions before administering to the patients. Call the Nuclear Medicine Department if you have any questions about the care of these patients.
2. Patients must remain in bed while visitors are in the room and visitors should remain at least three feet from the patient.
3. Radioactive patients are to be confined to their rooms except for special medical or nursing purposes, approved by the Nuclear Medicine Department.
4. No nurse, visitor or attendant who is pregnant or under the age of 18 years, should be permitted in the room of a patient who has received a therapeutic amount of radioactivity until the patient no longer presents a radiation hazard. Female visitors should be asked whether they are pregnant.
5. Attending personnel must wear rubber or disposable plastic gloves when handling urinals, bedpans, emesis basins or other containers having any material obtained from the body of the patient. Wash gloves before removing them and then wash hands. The gloves must be left in the patient's room in the designated waste container. These gloves need not be sterile or surgical in type.
6. Disposable items should be used in the care of these patients whenever possible. These items should be placed in the designated waste container. Contact the Nuclear Medicine Department for proper disposal of the contents of the designated waste container.
7. All clothing and bed linens used by the patient should be placed in the laundry bag provided and left in the patient's room to be checked by a member of the Nuclear Medicine Department.
8. All non-disposable items should be placed in a plastic bag and left in the patient's room to be checked by a member of the Nuclear Medicine Department.

ITEM #19

9. The patient will be instructed to void in the toilet and flush the toilet at least three times after use. If the patient is bedridden, a separate urinal or bedpan should be provided. The urinal or bedpan should be flushed several times with hot soapy water after use.
10. If the nurse helps to collect the excreta, she should wear disposable gloves. Afterwards, she should wash her hands with the gloves on and again after the gloves are removed. The gloves should be placed in the designated waste container for disposal by the Nuclear Medicine Department.
11. Disposable plates, cups, and eating utensils will be used by patients who are treated with Iodine-131.
12. Vomiting within 24 hours after oral administration, urinary incontinence, or excessive sweating within the first 48 hours may result in contamination of linen and/or floor. In any such situations, or if radioactive urine and/or feces is spilled during collection, call the Nuclear Medicine Department. Meanwhile, handle all contaminated material with disposable gloves and avoid spreading contamination.
13. All vomitus must also be kept in the patient's room for disposal by the Nuclear Medicine Department. Feces need not be routinely saved, unless ordered on the chart. The same toilet should be used by the patient at all times and it should be well flushed.
14. Utmost precautions must be taken to see that no urine or vomitus is spilled on the floor or the bed. If any part of the patient's room is suspected to be contaminated, notify the Nuclear Medicine Department.
15. If a nurse, attendant, or anyone else knows or suspects that his skin or clothing (including shoes) is contaminated, notify the Nuclear Medicine Department immediately. The person should remain in the patient's room and not walk about the hospital. If the hands become contaminated, wash immediately with soap and water.
16. If a therapy patient should need emergency surgery or should die, notify the Nuclear Medicine Department immediately.
17. When the patient is discharged, call the Nuclear Medicine Department and request that the room be surveyed for contamination before remaking the room.

ITEM #19

(2/85)

NURSING INSTRUCTIONS FOR PATIENTS TREATED WITH I-131

PATIENT'S NAME _____

ROOM # _____ PHYSICIAN'S NAME _____

RADIOISOTOPE ADMINISTERED _____

DATE AND TIME OF ADMINISTRATION _____

EXPOSURE RATES IN MR/HR

DATE	3 FEET FROM BED	10 FEET FROM BED
_____	_____	_____
_____	_____	_____
_____	_____	_____

COMPLY WITH ALL CHECKED ITEMS

- _____ 1. Visiting Time Permitted _____
- _____ 2. Visitors must remain _____ from patient.
- _____ 3. Patient may NOT leave room.
- _____ 4. Visitors under 18 NOT permitted.
- _____ 5. Pregnant visitors NOT permitted.
- _____ 6. Dosimeter Badges must be worn.
- _____ 7. Use and complete the following tags:

_____ door
_____ bed
_____ chart
_____ wrist

- _____ 8. Gloves must be worn while attending patients.
- _____ 9. Patient must use disposable utensils.
- _____ 10. All items must remain in room until ok'd by RSO
- _____ 11. Smoking is NOT permitted.
- _____ 12. Do not release room to admitting until ok'd by RSO.
- _____ 13. Other instructions:

IN CASE OF EMERGENCY CONTACT THE RADIATION SAFETY OFFICER

_____ RSO PHONE # _____

R. F. SCHINDERLE
Executive Director

SAINT JOSEPH HOSPITAL

333 NORTH MADISON STREET, JOLIET, ILLINOIS 60435 • 815/725-7133

February 8, 1985


F. Patrick McQuillan, M.D.
Glenwood Medical Group
2000 Glenwood Avenue
Joliet, Illinois 60435

Dear Doctor McQuillan:

Doctor Nicosia has requested Saint Joseph Hospital to indicate whether the hospital would accept, and whether the hospital possesses adequate facilities to hospitalize and monitor, whenever the need arises, any radioactive patients treated in your nuclear medicine section.

It has always been the policy of Saint Joseph Hospital to treat any patient in need of medical care. I do not see this policy changing with respect to any radioactive patient who might seek care here.

Sincerely,



R.F. Schinderle
Executive Director

RFS:ma

Item 25B

The "Procedure For Use of Group IV Radiopharmaceuticals for Treatment of Patients (I-131 Therapy)" given in Item 19 will be the Radiation Safety Precautions taken to the hospital((s) indicated in Item 25b.

A suitable survey meter capable of measuring the exposure rates emanating from the therapy patient will be used. Either the hospital(s) survey meter or the Victoreen 498 survey meter from the Glenwood Medical Group will be used for the patient and room surveys.

ITEM 25 C

CONTROL NO. 78348

(2/85)